M
Morria Biopharmaceuticals
Celsus Therapeutics is a drug development company focusing on novel anti-inflammatory, first-in-class synthetic drugs.
About Morria Biopharmaceuticals
Celsus Therapeutics is a biopharmaceutical company focused on developing groundbreaking therapies for inflammatory diseases. The company specializes in Multi-Functional Anti-Inflammatory Drugs (MFAIDs), which provide much-needed alternatives to traditional corticosteroids. Celsus Therapeutics operates in the healthcare and pharmaceutical markets, targeting conditions that involve chronic inflammation, such as cystic fibrosis (CF). The company primarily serves patients and healthcare providers looking for safer, long-term treatment options for inflammatory diseases.
Celsus Therapeutics' business model revolves around research and development (R&D) of novel drug candidates, followed by clinical trials to validate their efficacy and safety. Revenue is generated through private placements, partnerships, and potential future sales of approved drugs. The company recently announced a $75 million private placement, which underscores investor confidence in its innovative approach to treating inflammation.
Source: Dealroom company dataNews
Open roles
Morria Biopharmaceuticals in the London ecosystem
The Morria Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Morria Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Morria Biopharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


